DanaherDHR
DHR
About: In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Employees: 63,000
0
Funds holding %
of 7,315 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
120% more call options, than puts
Call options by funds: $1.53B | Put options by funds: $697M
4% more funds holding in top 10
Funds holding in top 10: 57 [Q4 2024] → 59 (+2) [Q1 2025]
0.32% less ownership
Funds ownership: 79.06% [Q4 2024] → 78.74% (-0.32%) [Q1 2025]
5% less funds holding
Funds holding: 2,280 [Q4 2024] → 2,174 (-106) [Q1 2025]
12% less capital invested
Capital invested by funds: $131B [Q4 2024] → $115B (-$16B) [Q1 2025]
18% less repeat investments, than reductions
Existing positions increased: 785 | Existing positions reduced: 953
28% less first-time investments, than exits
New positions opened: 152 | Existing positions closed: 210
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$225
14%
upside
Avg. target
$242
22%
upside
High target
$275
39%
upside
10 analyst ratings
10 positive
100%
0 neutral
0%
0 negative
0%
Scotiabank Sung Ji Nam | 39%upside $275 | Sector Outperform Upgraded | 11 Jul 2025 |
Evercore ISI Group Vijay Kumar | 14%upside $226 | Outperform Maintained | 8 Jul 2025 |
Barclays Luke Sergott | 14%upside $225 | Overweight Maintained | 24 Jun 2025 |
RBC Capital Conor McNamara | 26%upside $250 | Outperform Reiterated | 23 Apr 2025 |
Goldman Sachs Matthew Sykes | 21%upside $240 | Buy Maintained | 23 Apr 2025 |
Financial journalist opinion
Based on 7 articles about DHR published over the past 30 days
Positive
Seeking Alpha
2 weeks ago
Danaher: Biotech Momentum, Cost Cuts And Valuation Re-Rating Should Drive Upside
Danaher is positioned for a revenue rebound, led by strong bioprocessing demand and resilient recurring sales, despite short-term headwinds in Life Sciences and China. Margin outlook is stable, supported by a $150M cost-cutting program and proactive tariff mitigation. Shares trade below their 5-year average P/E, offering compelling upside, as growth recovers and margin initiatives take hold.
Neutral
Zacks Investment Research
2 weeks ago
CVS vs. DHR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now?
Neutral
PRNewsWire
2 weeks ago
Danaher Appoints Martin Stumpe as Chief Technology and AI Officer
WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer.
Neutral
PRNewsWire
2 weeks ago
Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences
WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021.
Positive
Zacks Investment Research
3 weeks ago
Why Danaher (DHR) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Seeking Alpha
3 weeks ago
Danaher: High Capex And Low Debt Despite Trump Legislation
The company has achieved returns on equity above 7.8% since 2019. Additionally, it reduced its liabilities-to-assets ratio to 35.72% this quarter, indicating a low risk of bankruptcy. Danaher expects an excellent growth outlook in the upcoming years, due to the significant investment that the biopharma industry has dedicated to developing new medical therapies. Between 2017 and 2024, Danaher invested 25.81% of its revenues to expand its operations, which has contributed to the growth rate of its revenues.
Neutral
PRNewsWire
3 weeks ago
Danaher Schedules Second Quarter 2025 Earnings Conference Call
WASHINGTON , June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour.
Positive
Zacks Investment Research
1 month ago
CVS vs. DHR: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical Services stocks have likely encountered both CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Neutral
Business Wire
1 month ago
Prosperity Partners Completes Acquisition of Danaher Attig & Plante
CHICAGO--(BUSINESS WIRE)--Prosperity Partners (“Prosperity”), a Chicago-headquartered tax and accounting business backed by Unity Partners LP (“Unity Partners”), today announced that it has completed the acquisition of South Burlington, Vermont-based tax and accounting firm Danaher Attig & Plante (“DAP”). Terms of the private transaction were not disclosed. Founded in 2005 and led by Cathy Attig and Matt Johnson, DAP provides sophisticated tax advisory and compliance services to individuals.
Neutral
Business Wire
1 month ago
SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Evocep--SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement.
Charts implemented using Lightweight Charts™